Show simple item record

Zugang zu COVID-19-Impfstoffen und Medikamenten: Ein globales öffentliches Gut
[working paper]

dc.contributor.authorHein, Wolfgangde
dc.contributor.authorPaschke, Annede
dc.date.accessioned2020-07-09T12:30:15Z
dc.date.available2020-07-09T12:30:15Z
dc.date.issued2020de
dc.identifier.issn1862-3581de
dc.identifier.urihttps://www.ssoar.info/ssoar/handle/document/68332
dc.description.abstractNew daily record numbers of infections worldwide exacerbate concerns about the impact of the COVID-19 pandemic on regions of the Global South. Weak health systems, vulnerable economies, and extreme inequalities threaten healthcare, livelihoods, and peace in many low- and middle-income countries. The risk of increasing infection rates remains imminent for all countries until a vaccine or medicine is available to everyone worldwide. While many low-income countries urgently need to "flatten the curve", rigid lockdown measures are difficult to impose in the vast informal sector and can mean a more imminent threat to lives and livelihoods by depriving millions of income and food. COVID-19 has already led to a world economic crisis through the breakdown of trade and rapidly increasing debts, and will only aggravate global inequalities even further. The key for slowing and eventually stopping the pandemic without lockdowns lies in the development of, and universal access to, effective drugs and vaccines, which are currently discussed on the highest political level as being "global public goods." An unprecedented initiative vis-à-vis the required collective action in global health is the Access to COVID-19 Tools Accelerator bringing together many important stakeholders in global health. Whether stakeholders will meet their commitments on access is not clear yet, as a three-way conflict intensifies between those demanding access to health products as a global public good, pharmaceutical firms offering compromises but defending patent-based exclusive rights, and "vaccine nationalism" by individual states. This pandemic could be an opportunity to realise access to vaccines and medi-cines for all. The high-level public debate about medicines as a global public good is unprecedented, and there are promising examples of collective action. It remains to be seen whether national governments and pharmaceutical companies can be held accountable by the defenders of a global public good approach regarding their publicly voiced commitment to "access for all."de
dc.languageende
dc.subject.ddcSozialwissenschaften, Soziologiede
dc.subject.ddcSocial sciences, sociology, anthropologyen
dc.subject.otherCOVID-19; Global Health Governance; Medikamentenzugangde
dc.titleAccess to COVID-19 Vaccines and Medicines - a Global Public Goodde
dc.title.alternativeZugang zu COVID-19-Impfstoffen und Medikamenten: Ein globales öffentliches Gutde
dc.description.reviewbegutachtetde
dc.description.reviewrevieweden
dc.source.volume4de
dc.publisher.countryDEU
dc.publisher.cityHamburgde
dc.source.seriesGIGA Focus Global
dc.subject.classozGesundheitspolitikde
dc.subject.classozHealth Policyen
dc.subject.thesozEntwicklungslandde
dc.subject.thesozdeveloping countryen
dc.subject.thesozKrankheitde
dc.subject.thesozillnessen
dc.subject.thesozGefährdungde
dc.subject.thesozendangermenten
dc.subject.thesozinternationale Zusammenarbeitde
dc.subject.thesozinternational cooperationen
dc.subject.thesozGesundheitswesende
dc.subject.thesozhealth care delivery systemen
dc.subject.thesozmedizinische Versorgungde
dc.subject.thesozmedical careen
dc.subject.thesozImpfungde
dc.subject.thesozvaccinationen
dc.identifier.urnurn:nbn:de:0168-ssoar-68332-2
dc.rights.licenceCreative Commons - Namensnennung, Keine Bearbeitung 3.0de
dc.rights.licenceCreative Commons - Attribution-NoDerivs 3.0en
ssoar.contributor.institutionGIGAde
internal.statusformal und inhaltlich fertig erschlossende
internal.identifier.thesoz10034610
internal.identifier.thesoz10035075
internal.identifier.thesoz10037880
internal.identifier.thesoz10037395
internal.identifier.thesoz10035401
internal.identifier.thesoz10034647
internal.identifier.thesoz10045567
dc.type.stockmonographde
dc.type.documentArbeitspapierde
dc.type.documentworking paperen
dc.source.pageinfo13de
internal.identifier.classoz11006
internal.identifier.document3
dc.contributor.corporateeditorGIGA German Institute of Global and Area Studies - Leibniz-Institut für Globale und Regionale Studien
internal.identifier.corporateeditor142
internal.identifier.ddc300
dc.description.pubstatusVeröffentlichungsversionde
dc.description.pubstatusPublished Versionen
internal.identifier.licence27
internal.identifier.pubstatus1
internal.identifier.review2
internal.identifier.series285
dc.subject.classhort10500de
ssoar.wgl.collectiontruede
internal.pdf.wellformedtrue
internal.pdf.encryptedfalse


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record